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Abstract
The P2X7 receptor (P2X7R) is attracting increasing attention for its involvement in cancer. Several recent studies have shown
a crucial role of P2X7R in tumour cell growth, angiogenesis and invasiveness. In this study, we investigated the role of the
two known human P2X7R functional splice variants, the full length P2X7RA and the truncated P2X7RB, in osteosarcoma cell
growth. Immunohistochemical analysis of a tissue array of human osteosarcomas showed that forty-four, of a total fifty-four
tumours (81.4%), stained positive for both P2X7RA and B, thirty-one (57.4%) were positive using an anti-P2X7RA antibody,
whereas fifteen of the total number (27.7%) expressed only P2X7RB. P2X7RB positive tumours showed increased cell
density, at the expense of extracellular matrix. The human osteosarcoma cell line Te85, which lacks endogenous P2X7R
expression, was stably transfected with either P2X7RA, P2X7RB, or both. Receptor expression was a powerful stimulus for
cell growth, the most efficient growth-promoting isoform being P2X7RB alone. Growth stimulation was matched by
increased Ca2+ mobilization and enhanced NFATc1 activity. Te85 P2X7RA+B cells presented pore formation as well as
spontaneous extracellular ATP release. The ATP release was sustained in all clones by P2X7R agonist (BzATP) and reduced
following P2X7R antagonist (A740003) application. BzATP also increased cell growth and activated NFATc1 levels. On the
other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to
NFATc1 and cell proliferation. All transfected clones also showed reduced RANK-L expression, and an overall decreased
RANK-L/OPG ratio. Mineralization was increased in Te85 P2X7RA+B cells while it was significantly diminished in Te85 P2X7RB
clones, in agreement with immunohistochemical results. In summary, our data show that the majority of human
osteosarcomas express P2X7RA and B and suggest that expression of either isoform is differently coupled to cell growth or
activity.
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Introduction
Osteosarcoma is the most common primary bone cancer,
accounting for approximately six percent of all new paediatric
tumours per year [1,2]. Histology of cancer lesions shows a
mixture of proliferating osteoblast cells, responsible for sclerosis,
and activated osteoclasts, responsible for bone resorption and
osteolysis. To date, few treatments to counteract pathologic bone
remodelling and alleviate the associated pain are available [1].
Among these the monoclonal antibody denosumab, which blocks
receptor activator of nuclear factor kB ligand (RANK-L), is giving
promising clinical results for treatment of cancer related bone
disorders [3]. The RANK-RANKL system is the main activator of
osteoclast formation and function. Osteoblast can express or
secrete either RANKL or its antagonist osteoprotegerin (OPG) to
induce osteoclasts mediated resorption or to stop it, respectively.
Interestingly, RANK-L levels have been suggested to be reduced
in advanced stage osteosarcoma [4].
Recent in vitro and in vivo evidence show that the P2X7
receptor (P2X7R) has a central role in carcinogenesis enhancing
tumour cell growth [5,6], tumour-associated angiogenesis [5] and
cancer invasiveness [7,8]. These data further support previous in
vitro reports demonstrating that P2X7R expression increases cell
proliferation [9,10], mitochondria and endoplasmic reticulum
Ca2+ levels [10,11], vascular endothelial growth factor (VEGF)
secretion [12], and agarose infiltration [13]. Furthermore, a
growing literature confirms early findings documenting an
increased P2X7R expression in human tumours (recently reviewed
in [14,15]). Although P2X7R is known to modulate osteoblast
proliferation and osteodeposition [16], no direct proof of P2X7R
involvement in bone cancers was available.
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The P2X7R is an ATP-gated ion channel that, upon sustained
stimulation with millimolar ATP concentrations, drives opening of
a non-selective large conductance pore that admits hydrophilic
molecules of MW up to 900 Da. Besides its natural ligand ATP,
the most potent, albeit non strictly selective, pharmacological
agonist is 29,39-(4-benzoyl)-benzoyl-ATP (BzATP). Several single
nucleotide polymorphisms (SNPs), either loss- or gain-of-function,
are known, some of them associated to diseases as different as
familiar chronic lymphocytic leukaemia, bipolar-disorders or
osteoporosis (recently reviewed in [17]). Moreover, nine different
naturally occurring human P2X7R splice variants (indicated as
P2X7RA to J) have been identified, P2X7RA being the well-
characterized full-length receptor [18,19]. Four out of the nine
splice variants, P2X7RB, P2X7RE, P2X7RG and P2X7RJ, lack
the extended C-terminal tail typical of P2X7RA. Among these,
P2X7RJ acts as dominant negative [19], while P2X7RB, unique
among truncated P2X7R splice variants, is a functional ion
channel, although unable to form the large conductance pore [18].
P2X7RB retains an intron between exons 10 and 11, causing the
addition of 18 extra aminoacids after residue 346 followed by a
stop codon. These modifications do not affect receptor pharma-
cology as P2X7RA and P2X7RB share the same agonists and
antagonists profile [18].
We recently investigated the effect of P2X7RB expression in
HEK293 cells, showing that, besides P2X7RA, also this isoform
exerts a trophic activity [13]. Co-expression of both P2RX7A and
B, which are expressed in many different human tissues, further
potentiated cell growth. Moreover, P2X7RA and B co-associated
on the plasma membrane increasing large conductance pore
opening, endoplasmic reticulum Ca2+ levels and NFATc1 activity
[13].
P2X7R is expressed in primary human osteoblasts, as well as in
primary rat osteoblasts and human osteosarcoma cell lines [20–
22]. Furthermore, data from p2rx72/2 mice show that lack of
P2X7R is associated to reduction of periosteal bone formation
[23] and osteogenic response to mechanical loading [24]. These
data are also corroborated by recent findings linking P2X7R SNPs
to osteoporosis [25]. Several P2X7R loss-of-function SNPs are
indeed associated to increased osteoporosis risk [26–28], while
gain-of-function variants are protective [29,30]. P2X7R is
expressed both in osteoblasts [20] and osteoclasts [31–33] and
might play a central role in osteoblasts-osteoclasts crosstalk via
calcium oscillations [34] and other signalling pathways [35].
P2X7R promotes osteogenesis by stimulating osteoblast prolifer-
ation as well as osteodeposition [16] through a series of different
pathways including c-fos [36], ERK [37], PI3K [38] and COX
[16]. Finally, P2X7R likely mediates osteoblast ATP release, as
P2X7R blockers inhibit ATP secretion [39,40].
Aim of our study was to shed light on the role of P2X7R in
human osteosarcoma and to reveal possible different effects of the
two isoforms A and B of the receptor. P2X7RA and B expression
was investigated in human osteosarcoma tissue arrays, whereas
their function was assessed by transfection into the human
osteosarcoma Te85 cell line. Our data reveal that P2X7R isoforms
are widely expressed in human osteosarcomas, and that they
differently modulate cell proliferation and mineralization.
Materials and Methods
Reagents and antibodies
Whole cell culture reagents, lipofectamine LTX, RNA extrac-
tion PureLink Kit and Fura 2 AM were purchased from Life
technologies (Milan, Italy). Taq Man Reverse transcription kit was
from Roche (Milan, Italy), whereas anti P2X7 polyclonal antibody
(also referred as anti-P2X7R-Cter), BzATP (29,39-(4-benzoyl)-
benzoyl-ATP), cell dissociation solution, bovine serum albumin
(BSA), ethidium bromide, sulfinpyrazone, hygromycin B, cyclo-
sporin A (CSA), apyrase, Mayer’s haematoxylin, dexamethasone,
ascorbic acid and alizarin red S were from Sigma-Aldrich (Milan,
Italy). Anti-P2XR7 monoclonal antibody (mAb), targeting the
extracellular loop of P2X7R [41] (also referred as anti-P2X7R-ec),
was kindly provided by Professor James Wiley (Florey Neurosci-
ence Institutes, University of Melbourne, Australia). Secondary,
HRP-conjugated, goat anti-rabbit and goat anti-mouse antibodies,
and Liquid diaminobenzidine (DAB) Substrate Chromogen
System were from Dako (Milan, Italy). Anti-Ki67 rabbit polyclonal
antibody and NBT/BCIP plus suppressor were from Thermo
Scientific (Rockford, IL, USA). Alkaline phosphatase (AP)-
conjugated goat anti-rabbit antibody was from Bethyl (Montgom-
ery, TX, USA). Access RT-PCR system kit and ENLITEN
rLuciferase/Luciferin reagent were purchased from Promega
(Milan, Italy). G418 sulphate was from Calbiochem (La Jolla,
CA, USA). A740003 was from Tocris (Ellisville, MO, USA).
Immunohistochemistry and tumour specimens cell
counts
A panel of 54 different osteosarcoma specimens was analysed
using tissue array slides CV2 human, osteosarcoma Super Biochips
(Super Biochips, South Korea distributed by Tema Ricerca,
Bologna, Italy). Human samples were collected by Super Biochips
according to Korean and United States laws (Code of federal
regulation 45CFR 46.101(b)) ensuring that rights, welfare and
privacy of human subjects were protected. An External Review
Board, composed of pathologists from major hospitals and legal
experts, also reviewed procedures. Slides were heated at 60uC for
20 min, deparaffinized with xylene and rehydrated by sequential
passages through decreasing concentrations of ethanol. Endoge-
nous peroxidase activity was blocked by 15 min incubation at
room temperature with 0.3% H2O2 in TBS (50 mM Tris,
150 mM NaCl, pH 7,6). After three rinses in wash buffer
(0.025% Triton X-100 in TBS), tissue sections were maintained
for 2 hours at room temperature with a blocking solution (1%
BSA, 10% FBS in TBS), and incubated overnight at 4uC with
either a mouse anti-P2X7R mAb (anti-P2X7R-ec) (65 mg/ml) or a
rabbit polyclonal anti-P2X7R antibody (anti-P2X7R-Cter)
(20 mg/ml) in incubation solution (1% BSA in TBS). Sections
were rinsed twice in wash buffer, incubated for 60 min at room
temperature with appropriated HRP conjugated secondary
antibodies (goat anti-mouse and goat anti-rabbit, respectively)
diluted 1:100 in incubation solution, washed in TBS, and
submitted to 6–10 min incubation at room temperature with
Liquid diaminobenzidine (DAB) Substrate Chromogen System
(Dako). Counterstaining was performed with Mayer’s haematox-
ylin. The same procedure was applied to 5 mm tissue sections from
tumours obtained by sub-cutaneous inoculation of either
HEK293-mock or HEK293-P2X7RA cells into nude mice (see
[5]), used as negative and positive controls, respectively. Double
immunostaining was performed applying simultaneously the two
anti-P2X7R antibodies, at the same conditions as above.
Furthermore, co-immunostaining using the monoclonal anti-
P2X7R-ec plus a polyclonal anti-Ki67 antibody (diluted 1:10 in
incubation solution) was carried out after antigen unmasking
performed for 30 min at 160uC in citrate buffer, pH 6.0. In both
cases, after washes, slides were incubated with a mix of the two
secondary antibodies, i.e. an anti-mouse HRP conjugated and an
anti-rabbit AP conjugated. Chromogens were finally applied
sequentially: DAB first and NBT/BCIP plus suppressor subse-
quently. Counterstaining was carried out as above. Images were
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acquired with a Nikon Eclipse H550L microscope (Nikon, Firenze,
Italy) using the NIS-Elements software (Nikon). Tumour cell
numbers were evaluated by counting haematoxylin stained nuclei
with Image J software (Image J1.47v Wayne Rasband, NIH,
USA).
Cell cultures and transfections
Human osteosarcoma Te85 cell line [42] was previously used in
Gartland’s laboratory [20]. Cells were grown in DMEM+
Glutamax medium supplemented with 10% FBS, 100 U/ml
penicillin and 100 mg/ml streptomycin (complete culture medi-
um). Plasmids containing human P2X7RA and P2X7RB were
previously obtained in our laboratory [10,13] respectively by
inserting P2X7RA sequence in pcDNA 3.1 vector, carrying
gentamicin resistance, and P2X7RB sequence in pcDNA 3.1
Hygro, containing hygromicin B resistance. Te85 cells expressing
P2X7RA (Te85-P2X7RA), P2X7RB (Te85-P2X7RB), both
(Te85-P2X7RA+B) or the empty vectors (Te85-mock) were
obtained by transfection with lipofectamin LTX and antibiotic
selection with either G418 sulphate (0.8–0.2 mg/ml), hygromicyn
(0.2–0.1 mg/ml) or both, as previously described [13]. Serial
dilutions allowed obtaining single cell clones that were tested at
fluorimeter for changes in cytosolic Ca2+ concentration and
ethidium bromide up-take (see below). Among all clones evaluat-
ed, at least two for each cell type were employed for subsequent
experiments. Where not reported data obtained with Te85-mock
cells were not significantly different from Te85-wt controls.
RNA extraction
Cells lysates were obtained with TRIZOL reagent (Life
technologies), and RNA was extracted using PureLink RNA Mini
Kit. RNA content was determined using a Nanodrop 2000
spectrophotometer (Thermo Scientific, Milano, Italia) and RNA
integrity was checked by electrophoresis on 1.5% agarose gel in
Tris Borate EDTA (TBE) (89 mM Tris, 89 mM boric acid,
20 mM EDTA, pH 8.0). Gels were analysed by a RED analyser
(Cell Biosciences, Santa Clara, CA, USA).
RT-PCR
Semi quantitative PCR was performed as previously described
[13] with Promega RT-PCR access kit (Promega, Milan, Italy)
using 200–500 ng RNA/sample as template. Primers used were:
Forward 59 AGATGCTGGAGAATGGAGTG 39, reverse 59
TTCTCGTGGTGTAGTTGTGG 39 for P2X7RA.
Forward 59 CCCATCGAGGCAGTGGA 39, Reverse 59
TTCTCGTGGTGTAGTTGTGG 39 for P2X7RB.
Forward 59GAAAATGGAGCTCCTGGTCA 39, Reverse
59ACCATTGGCACCTTTAGCAC 39, for collagen I.
Forward 59 CCTCTGACTTCAACAGCCAC 39, Reverse 59
CATGACAAGGTGCGGCTCCC 39 for G3PDH.
Flow Cytometry
Two million cells were re-suspended in PBS with the addition of
200 mg of anti-P2X7R-ec (see reagents and antibodies) at a final
concentration of 25 mg/ml. Secondary antibody was an anti-
mouse FITC-conjugated rabbit polyclonal antibody diluted 1:200.
Fluorescence was measured using a BD FACScan flow cytometer
(Becton Dickinson, Milan, Italy), data were analysed with BD cell
quest software and expressed as Mean Fluorescence Intensity after
subtraction of secondary antibody values.
Measurement of intracellular calcium concentration
([Ca2+]i)
Changes in the cytosolic free Ca2+ concentration were measured
in a thermostat controlled (37uC) and magnetically stirred Cary
Eclipse Fluorescence Spectrophotometer (Agilent Technologies,
Cernusco SN, Milan, Italy) with the fluorescent indicator fura-2/
acetoxymethyl ester (fura-2/AM) as previously described [10].
Briefly, 26106 cells were loaded with 2 mM fura-2/AM for 30 min
in the presence of 250 mM sulfinpyrazone in saline solution
(125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM NaH2PO4,
20 mM HEPES, 5.5 mM glucose, 5 mM NaHCO3, and 1 mM
CaCl2, pH 7.4), rinsed, and re-suspended at a final concentration
of 106/ml in the same buffer. When required, cells were re-
suspended in Ca2+-free saline. Excitation ratio and emission
wavelength were 340/380 and 505 nm, respectively.
Measurement of plasma membrane permeabilization
Increases in plasma membrane permeability were measured by
monitoring the ethidium bromide up-take. Briefly, 56105 cells
were re-suspended in Ca2+-free saline solution, incubated in a
thermostat controlled (37uC) and magnetically stirred fluorimetric
cuvette in the presence of 20 mM ethidium bromide and
challenged with the agonist. Full permeabilization was obtained
by adding digitonin (100 mM) at the end of the experiment.
Fluorescence emission was measured at an excitation/emission
wavelength couple of 360/580 nm.
Extracellular ATP measurement
Extracellular ATP was measured in the culture supernatants
with ENLITEN rLuciferase/Luciferin reagent, as per manufac-
turer’s instructions. Briefly, 56104 cells per well were plated in 96
well plates. Following adhesion cells were incubated for 24 hours
in the presence or absence of the required stimuli or inhibitors.
Luminescence from cell supernatants was measured following
addition of 100 ml of ENLITEN reagent per well, in a Victor2
Perkin Elmer luminometer (Perkin Elmer, Wellesley, MA, USA).
Proliferation assay
For cell growth assay 105 cells/ml were plated in 6-well plates in
DMEM+Glutamax medium without FBS and maintained at 37uC
in a CO2 incubator. Cells were counted at various time intervals
(24, 48, 72 hours) in a Bu¨rker chamber with a phase contrast
Olympus microscope (Olympus Life Science Europe, Hamburg,
Germany).
NFATc1 activation assay
Nuclear extracts were obtained with the nuclear Extract Kit
(Active Motif, Rixensart, Belgium). The NFATc1 activation assay
was performed using a nuclear extract from PHA-stimulated
Jurkat cells for comparison with the TransAM NFATc1 ELISA kit
(Active Motif, Vinci, Biochem, Vinci, Italy) as per manufacturer’s
instructions.
Real-time PCR
Expression of receptor activator of nuclear factor kappa B-
ligand (RANK-L) and osteoprotegerin (OPG) was determined by
real-time PCR in a Step One Real-Time PCR system (Applied
Biosystems). Reverse transcription was performed starting from
1 mg of RNA/sample using the High capacity cDNA Reverse
transcription kit (Applied Biosystems) following manufacturer’s
instructions. For real-time PCR, 2 ml of cDNA were used as
template. Amplification was performed with predesigned Taqman
probes (Applied Biosystem) for RANK-L, OPG and GAPDH as
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reference mRNA. A comparative CT experiment (DDCT) was run
to allow determination of the change of expression (fold increase)
of the target cDNA in the test sample relative to Te85 wt reference
sample.
Mineralization
Cells were seeded at a density of 105 cells per well of 48-well
plates, and cultured in complete culture medium. Once confluent,
cells were cultured for 14 days with osteogenic medium (DMEM+
0.5% FCS +10 nM dexamethasone +50 mg/ml ascorbic acid),
with medium change every 2–3 days. After 14 days, the osteogenic
medium was supplemented with 5 mM inorganic phosphate and
cells were cultured for further 7 days, with medium change every
2–3 days. On completion of the culture, the cells were washed
twice with PBS and fixed with 100% ethanol for at least 1 hour at
4uC. After fixation, cells were washed Twice with PBS and
incubated in 40 mM alizarin red S (pH 4.2) for 90 min on an
orbital shaker. The excess, unbound stain was completely removed
by washing cells with 95% ethanol. The plates were then left to
air-dry overnight, before scanning in a flatbed scanner at 1200 dpi
and images analysed using Image J software.
Statistics
Unless otherwise stated, data shown are mean 6 SE. Test of
significance was performed with Student’s t test using Graphpad
InStat (GraphPad Software Inc, San Diego, CA, USA). Coding:
*p,0.05, **p,0.01, ***p,0.001.
Results
Human osteosarcomas express P2X7RA and P2X7RB
A tissue array containing samples from 54 stage IV osteosar-
comas was screened for P2X7RA and B expression by immuno-
histochemistry. Specimens included mainly osteoblastic and
chondroblastic osteosarcomas from 39 male and 15 female
patients, in the 5 to 61 age range. Two different antibodies were
employed. A P2X7RA-selective polyclonal Ab, directed against
the P2X7RA-specific C-terminal tail, here abbreviated as anti-
P2X7R-Cter, and a monoclonal antibody recognizing both
P2X7RA and B since raised against the extracellular domain
common to both isoforms, here shortened as anti-P2X7R-ec.
Antibodies reactivity was firstly checked on specimens from
tumours obtained following inoculation of HEK293-mock and
HEK293-P2X7RA cells into nude mice (not shown). Represen-
tative osteosarcoma samples stained by the two different antibodies
are presented in Figure 1 (panels A-D). Of the osteosarcomas
analysed, the great majority (44/54) (81.4%) stained positive with
the anti-P2X7R-ec mAb, while 31/54 (57.4%) resulted positive
with the anti-P2X7R-Cter Ab. Twenty nine samples (53.7%)
resulted P2X7RA+B positive since labelled by both the anti-
P2X7R-Cter Ab as and the anti-P2X7R-ec mAb (Figure 1E),
whereas 15/54 (27.7%) resulted positive only for P2X7RB as
staining was exclusively obtained using the anti-P2X7R-ec mAb,
but not the anti-P2X7R-Cter Ab (Figure 1G,H). Evaluation of the
number of cells per microscopic field demonstrated that osteosar-
comas expressing uniquely P2X7RB were characterized by a
higher cell density than osteosarcomas positive for both P2X7RA
and B (Figure 1I). This was also confirmed by evaluation at double
immunostaining of Ki67 labelled nuclei (Figure 2A–D). The
number of Ki67 positive nuclei was higher in osteosarcomas
positive uniquely for P2X7RB than in P2X7RA+B positive
tumours (373.3631.9 vs 189.3640.9). Co-immunostaining of
P2X7RA+B tumours with the two anti-P2X7R antibodies
(Figure 2E–H) showed the presence of a mix of cells among
which some were positive for P2X7RB only, whereas others
resulted labelled for both isoforms (arrows in Figure 2G,H).
Overall these results show that P2X7R is expressed in osteosar-
Figure 1. Human osteosarcomas express P2X7RA and P2X7RB.
Paraffin embedded osteosarcoma tissue array was assayed by
immonohistochemistry for P2X7R expression (see Materials and
Methods) and representative samples are shown. (B): osteosarcoma
stained with a polyclonal antibody recognizing P2X7R C-terminal
domain (anti-P2X7R-Cter). (D): osteosarcoma stained with a monoclonal
antibody recognizing P2X7R extracellular domain (anti-P2X7R-ec). (A,C):
control samples with appropriate secondary antibodies. (E–H): differ-
ential expression of P2X7R isoforms. (E,G): staining with anti-P2X7R-Cter.
(F,H): staining with anti-P2XR7-ec. (E,F): representative osteosarcoma
stained with both antibodies (P2X7RA+B positive). (G,H): representative
osteosarcoma stained only with anti-P2X7Rec (P2X7RB only positive).
(I): number of cells per microscopic (40x) field in P2X7RA+B positive
(purple) or P2X7RB only positive (cyan) tumour specimens. Cells were
counted as described in Materials and Methods. Data are shown as
means 6 SE (N= 8, ***p,0.001).
doi:10.1371/journal.pone.0107224.g001
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comas and point out a link between P2X7RB expression and
increased cell density.
Expression and functional characterization of P2X7R in
Te85 osteosarcoma cells
High P2X7R expression by human osteosarcomas makes it
difficult to investigate the effect of receptor overexpression in
osteosarcoma cells. We thus used as a model the Te85 human
osteosarcoma cell line which lacks endogenous P2X7R protein
expression. Te85 cells were transfected with P2X7RA, P2X7RB
or co-transfected with both (P2X7RA+B). Receptor expression
was assessed by both RT-PCR and flow cytometry (Figure 3). RT-
PCR showed a 400 bp band, corresponding to P2X7RA
amplicon, in Te85-P2X7RA and in Te85-P2X7RA+B cells, while
a 500 bp band, corresponding to P2X7RB, was detected in Te85-
P2X7RB and Te85-P2X7RA+B cells (Figure 3A). Te85-wt cells
and all P2X7R-transfected cells expressed collagen I as a marker
of osteoblast differentiation (Figure 3A). Flow cytometry analysis,
performed using the anti-P2X7R-ec mAb, showed that plasma
membrane P2X7RA expression was higher than P2X7RB, and
that the highest level of cell surface expression was achieved in
Te85 cells transfected with both P2X7RA and P2X7RB (p,0.05
for P2X7RA+B versus P2X7RA) (Figure 3B). Stimulation with
500 mM BzATP (corresponding to the EC50 for P2X7RB which
has a lower affinity for ATP than the full length P2X7RA [13])
triggered a [Ca2+]i rise in all transfected clones (Figure 3C). Ca
2+
increments occurred in the following order: Te85-P2X7RB ,
Te85-P2X7RA , Te85-P2X7RA+B (Figure 3D). This response
might depend on the different plasma membrane expression level
of the diverse isoforms (P2X7RB the lowest, P2X7RA+B the
highest), or on the activation of the receptor-associated large
conductance pore. To clarify this issue we tested pore formation in
Te85 transfectants. As shown in Figure 3E, F, P2X7RB did not
support any plasma membrane permeabilization, a result expected
due to lack of the extended cytoplasmic C-tail associated to pore
opening [13]. Unexpectedly, this was also the case for P2X7RA,
which usually gates the large conductance pore. Interestingly,
pore-forming activity was restored in Te85 cells transfected with
both P2X7R variants (Figure 3E, F). To sum up, in order to
reproduce the typical P2X7R signature in Te85 osteosarcoma
cells, expression of both P2X7RA and B isoforms is clearly needed.
P2X7R transfection triggers extracellular ATP release,
NFATc1 activation, and drives proliferation of Te85
osteosarcoma cells
Extracellular ATP release from Te85 wt and transfected cells
was measured. Among all cell lines tested, only Te85 cells
transfected with both P2X7RA and B showed a significantly
higher value than Te85 wt cells (Figure 4A). Therefore, pore
formation found in Te85 P2X7RA+B cells appears related to
extracellular ATP release. Extracellular ATP was significantly
increased in all transfectants by BzATP treatment, reduced by the
selective P2X7R antagonist A740003, and fully abrogated upon
administration of the ATP degrading-enzyme, apyrase (Fig-
ure 4A).
Intracellular calcium mobilization is one of the main stimuli
leading to activation of the nuclear factor of activated T cells
complex 1 (NFATc1) which has been associated to P2X7R-
dependent proliferation [11] and is also known to be central in
osteoblast biology [43]. Analysis of NFATc1 nuclear translocation
showed that all P2X7R-transfected Te85 clones had significantly
higher nuclear NFATc1 levels than Te85 wt cells, although no
major differences were observed among the transfected clones
(Figure 4B). BzATP treatment significantly increased the levels of
activated NFATc1 in all clones whereas cyclosporin A (CSA), a
well known NFATc1 inhibitor, took the NFATc1 activation levels
back to that of Te85 wt control cells (Figure 4B).
Converging evidence from different laboratories show that both
P2X7RA and B are endowed with a strong growth-promoting
activity [10,13,44,45], and in particular P2X7RA is overexpressed
in many human malignant tumours [46–49]. To check whether
P2X7R might also support osteosarcoma cell growth, we
investigated the effect of P2X7R isoforms on Te85 cell prolifer-
ation. P2X7R expression was indeed a powerful stimulus for cell
growth, the most efficient growth-promoting isoform being
P2X7RB (Figure 5A). Treatment with either apyrase or
A740003, significantly reduced, whereas BzATP stimulation
significantly increased, the proliferative capability of all transfec-
tants (Figure 5B). This suggests the existence of an ATP-mediated
loop controlling and sustaining cell proliferation. To confirm the
central role played by NFATc1 in P2X7R-sustained proliferation,
Figure 2. Double immunohistochemistry on human osteosar-
comas. Co-immunostainings of osteosarcoma tissue array either with
the anti-P2X7R-ec plus anti-Ki67 antibodies (A–D), or with the two
primary anti-P2X7R antibodies (E–H) were carried out as described in
Materials and Methods. (A,C): representative P2X7RB positive osteosar-
coma showing a higher number of Ki67 positive nuclei (stained in blue)
respect to a representative P2X7RA+B tumour (B,D). (E–H): representa-
tive P2X7RA+B positive tumours demonstrating the presence of a mix
of cells some (stained in brown) positive for P2X7RB only, some others
(stained in blue-brown) positive for both P2X7RA and B. Two different
magnifications, 20x (A,B,E,F) and 40x (C,D,G,H) are shown.
doi:10.1371/journal.pone.0107224.g002
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Figure 3. Characterization of P2X7R isoforms A and B expressed in Te85 transfected clones. (A): RT-PCR showing selective expression of
P2X7RA or P2X7RB in Te85 clones. Housekeeping control gene was G3PDH, osteoblast specific gene was collagen I. (B): P2X7R surface expression
determined by flow cytometry with anti-P2X7R-ec. Graph shows the Mean Fluorescence Intensity (MFI) after subtraction of secondary antibody
values. Data are shown as means 6 SE, N = 3. ***P,0.001 versus Te85 wt; ###P,0.001 versus Te85 P2RX7B; 1P,0.05 versus Te85 P2RX7A. (C):
Representative traces showing intracellular calcium increment following stimulation with 500 mM BzATP. (D): Calcium variations evoked by P2X7R
activation showed as means 6 SE, N= 10. ***p,0.001 versus Te85 wt. (C): Representative traces showing ethidium bromide uptake following
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the effect of CSA was tested on Te85 cell growth. As shown in
Figure 5B, CSA reduced BzATP-induced proliferation of all
transfectants proving the reliance of P2X7R-dependent prolifer-
ation on NFATc1 activation in our model.
P2X7R expression modulates RANK-L, OPG and
mineralization
Function of P2X7R on osteosarcoma biology was further
investigated by checking the expression of two crucial molecules
for bone homeostasis, i.e. receptor activator of nuclear factor
stimulation with 500 mM BzATP. (D): Percentages of ethidium permeabilization on digitonin control showed as means 6 SE, N = 10. ***p,0.001
versus Te85 wt. Colour coding: green Te85 wt, red Te85 P2X7RA, cyan Te85 P2X7RB, purple Te85 P2X7RA+B.
doi:10.1371/journal.pone.0107224.g003
Figure 4. P2X7RA and B increase ATP release and NFATc1 activity in Te85 transfected cells. (A): Extracellular ATP was measured in the
culture supernatants with ENLITEN rLuciferase/Luciferin reagents as described in materials and methods. Te85 clones were plated at 5x105 cells per
well in 96 well plates and, following adhesion, incubated for 24 hours in the absence (untreated) or presence of either 100 mM BzATP, 100 mM
A740003 or 4 U/ml Apyrase. ATP release was expressed as fold increase over Te85 wt reference sample. Data are means 6 SE; N= 3. (B) Nuclear
fractions of the different clones were obtained as described in materials and methods. Activated NFATc1 was measured by ELISA in absence
(untreated) or in presence of either 50 mM BzATP or 10 mM cyclosporin (CSA). CSA vehicle (DMSO) was used as control. Results are compared to
nuclear NFATc1 levels in Jurkat cells stimulated with PHA supplied by manufacturer. In graph means 6 SE of absorbance are shown, N= 9. Colour
coding: green Te85 wt, red Te85 P2RX7A, cyan Te85 P2RX7B, purple Te85 P2RX7A+B.
doi:10.1371/journal.pone.0107224.g004
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kappa B-ligand (RANK-L) and osteoprotegerin (OPG). While
RANK-L messenger was reduced in all P2X7R-expressing clones
(Figure 6A), OPG mRNA was significantly increased only in
P2X7RB transfected cells (Figure 6B). However, the RANK-L/
OPG ratio was decreased in all P2X7R clones. A reduced RANK-
L/OPG ratio is generally associated in vivo with decreased bone
resorption, a powerful boost for bone mass and a feature of
osteosclerotic lesions. Finally, the effect of P2X7R expression on
mineralization, another relevant osteoblastic activity, was assessed.
In this case, the transfection with the two isoforms had quite
different effects (Figure 6C). P2X7RA alone did not significantly
modify mineralisation as compared to Te85 wt cells. On the
contrary, expression of P2X7RB caused a striking reduction of
mineralisation respect to Te85 wt and Te85-P2X7RA, whereas a
significant increase was observed in cells transfected with both
P2X7RA and B variants (Figure 6C).
Figure 5. P2X7RA and B increase cell growth in Te85 transfected cells. (A): Te 85 clones were plated at a 105 cells/ml in 6 well plates in cell
culture medium without FBS. Percentage of viable cells was evaluated at the different time points as described in materials and methods. The graph
shows means 6 SE, N = 12. *p,0.05, ***P,0.001 versus Te85 wt control; #p,0.05 versus Te85 P2RX7A+B, $p,0.05 versus Te85 P2RX7A. (B) Cell
proliferation assessed for 24 hours in absence (untreated) or presence of: 4 U/ml Apyrase, 100 mM A740003, 100 mM BzATP, 100 mM BzATP +10 mM
cyclosporin (CSA). A740003 and CSA vehicle (DMSO) was used as control. The graph shows means 6 SE, N= 3. Colour coding: green Te85 wt, yellow
Te85mock, red Te85 P2RX7A, cyan Te85 P2RX7B, purple Te85 P2RX7A+B.
doi:10.1371/journal.pone.0107224.g005
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Discussion
Interaction of tumour cells with ligand molecules present in the
tumour microenvironment is central in cancer growth and
progression. ATP recently emerged as an extracellular messenger
present at high levels in the tumour microenvironment [50–52],
but the effect of this molecule on carcinogenesis is yet incompletely
known. In a recent paper we demonstrated that P2X7R is
involved in tumour growth and neo-vascularization in vivo [5].
These data corroborated previous results showing that the P2X7R
supports proliferation of lymphocytes [9], osteoblasts [16] and
osteosarcoma cells [53].
In the present study, we report that human osteosarcomas
express at high level the full length P2X7RA and the truncated
P2X7RB isoforms, two variants previously shown to support cell
proliferation [13]. Staining with two different antibodies recog-
nizing either both isoforms or P2X7RA only, allows us to conclude
that most osteosarcomas analysed express both P2X7RA and
Figure 6. P2X7RA and B expression reduces RANK-L while differently modulates OPG messenger and mineralization. RANK-L and
OPG mRNA levels were evaluated by real-time PCR as described in Materials and Methods. Messenger expression was normalized on G3PDH internal
control and displayed as fold increase over Te85 wt reference sample. (A): RANK-L mRNA expression (B): OPG mRNA expression. Data are shown as
mean 6 SE, N= 12, ***p,0.001 versus Te85 wt. (C): Mineralization by Te85 clones was assessed over a 21 days period as described in Materials and
Methods. (A): Quantification of the amount of alizarin red S staining of each clone. Data are shown as means6 SE (N= 6) analysed by Kruskal-Wallace
test with Dunn’s multiple comparison post-test. ***P,0.001 versus Te85 wt and Te85-P2X7RA; *P,0.05 vs Te85 wt; $$P,0.01 versus Te85 P2X7RA.
Colour coding: green Te85 wt, red Te85 P2X7RA, cyan Te85 P2X7RB, purple Te85 P2X7RA+B.
doi:10.1371/journal.pone.0107224.g006
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P2X7RB. The possibility that isoforms different from P2X7RA or
P2X7RB are recognized by the anti-P2X7R-ec antibody is very
unlikely as all other splice variants (P2X7RC-J) either loose or gain
introns in the extracellular domain recognized by the antibody
[41]. On the other hand, if expressed, non-functional P2X7RC,
P2X7RD, P2X7RF and P2X7RH isoforms would be recognized
by anti-P2X7R-Cter as they carry the same C-terminal tail as
P2X7RA. However, positivity of 27.7% of total osteosarcomas just
for the anti-P2X7R-ec strongly suggests that the only variant
expressed by these tumours is P2X7RB. Furthermore, the finding
that P2X7RB positive osteosarcomas showed higher cell density
and increased Ki67 positivity than those expressing both isoforms
indicates a relationship between P2X7RB expression and
enhanced cell proliferation.
P2X7R might sustain osteosarcoma growth in an autonomous
fashion thanks to autocrine/paracrine ATP release. Further, it
might also modulate osteosarcoma cell interaction with other bone
cells by regulating release of key molecules such as RANK-L and
OPG or by affecting osteodeposition. To deeply investigate these
points, Te85 osteosarcoma cells, lacking endogenous P2X7R
protein expression, were stably transfected with either P2X7RA,
P2X7RB or both. Our data show that all P2X7R-transfected Te85
osteosarcoma clones displayed increased proliferation, compared
to Te85 wt or Te85 mock cells, thus confirming a trophic activity
of P2X7R also in this tumour. Receptor stimulation by BzATP
significantly increased proliferative activity of all transfected
clones, Te85 P2X7RB cells presenting the highest growth ability.
The latter result is in agreement with the immunostaining of
osteosarcomas in which the truncated P2X7RB isoform was
present and related to higher cell number. Central to P2X7R
mediated proliferation is NFATc1 activation. This nuclear factor,
besides being one of the recognized mediators of P2X7R
dependent growth [11], is also a known determinant of osteoblast
proliferation [43] and bone formation [54]. NFATc1 activity was
indeed increased in all P2X7R transfectants, improved by BzATP
and decreased by CSA treatment.
Interestingly, P2X7RA and P2X7RB isoforms have differential
effects on cell growth and on mineralization. In fact, P2X7RB,
which is unable to generate the large conductance pore, confers
the highest growth drive, while strongly reduces osteodeposition.
On the contrary, P2X7RA causes a smaller increase in cell
growth, whereas mineralization is not significantly different from
that observed in the Te85 wt cells. Finally, co-transfection with
Figure 7. Schematic summary of obtained data and hypothetical deductions.
doi:10.1371/journal.pone.0107224.g007
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both isoforms causes a cell growth increase comparable to that of
P2X7RA alone but a stronger stimulus for mineralization.
Previous studies reported atypical P2X7R pharmacology in
osteosarcoma cell lines [22]. Accordingly, our data show that, in
order to produce P2X7R full-blown physiological signature, i.e.
formation of both channel and large conductance pore, expression
of P2X7RA in Te85 cells is not sufficient but co-expression of the
shorter variant (P2X7RB) is also required. In fact, only Te85
P2XR7A+B cells undergo a small but significant permeabilization
to high molecular weight solutes, possibly due to either increased
cell surface expression, as detected at flow cytometry, or
interaction with a different subset of intracellular proteins [55].
P2X7RA+B dependent pore forming activity was accompanied by
increased spontaneous ATP release that could possibly enhance
mineralization [13,40,56]. Increased proliferation and reduced
bone deposition characterizing Te85 P2X7RB cells might be
suggestive of a de-differentiated phenotype. This is also indicated
by the reduced extracellular matrix in osteosarcomas positive at
immunostaining for P2X7RB compared to that of tumours
positive for both P2X7RA and P2X7RB. In summary, the
opposite effects of P2X7RB and P2X7RA+B on osteosarcoma cell
growth and mineralization (Figure 7), suggests that P2X7R as an
ion channel is predominantly involved in cell proliferation, while
activation of the P2X7R-associated large conductance pore might
be chiefly responsible for the differentiation-associated effects.
A role for P2X7R in bone formation is supported by the
findings of Panupinthu et al. [16] who found that osteoblasts
isolated from P2X7R-deficient mice showed reduced bone
deposition. Contrary to these findings, other in vitro reports
suggest that ATP spontaneously released from rat osteoblasts and
acting at P2X7R was responsible for reduced bone formation [57].
In our experimental model, P2X7R-mediated ATP release seems
related to augmented mineralizing activity, as shown by
P2X7RA+B expressing cells behaviour. Additionally, our study
points out differences between the two isoforms, in particular
showing a relation between P2X7RB expression and proliferation,
likely at the expense of bone mineralization. The small number of
human osteosarcomas analysed and limited clinical data in our
possession do not allow us to conclude whether osteosarcomas
expressing P2X7RB behave more aggressively. Analysis of a larger
patient sample will help in clarifying this issue.
P2X7R transfection also affects expression of RANK-L and
OPG, two crucial molecules in bone remodelling. Osteosarcomas
generally exhibit altered bone remodelling due to either excessive
deposition or osteolysis. Our data show that P2X7R expression
significantly reduces RANK-L messenger levels in all transfectants.
Instead, OPG levels were increased only in Te85 P2X7RB.
Nevertheless, RANK-L/OPG ratio was reduced in all P2X7R
expressing clones. A low RANK-L/OPG ratio on one hand will be
beneficial for osteosarcoma patients, as it decreases osteolysis and
related pain [58], whereas, on the other, it will be negative as it
increases invasiveness [4,59].
In conclusion, our study demonstrates expression and trophic
activity of P2X7R receptor isoforms A and B in human
osteosarcoma. These data support a role of P2X7R in osteosar-
coma growth and bone remodelling and point to P2X7 receptor as
a potential target for osteosarcoma therapy.
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